Category: New products
-
Weather Balloon Data Company Raises $6M in Seed Funds
A company creating a network of long-range high-altitude balloons to expand the scope of global weather forecasting is raising $6 million in seed funds.
-
Engineered T-Cells Shown Safe, Reduce Myasthenia Gravis
Results of a small clinical trial show genetically altered T-cells from patients with myasthenia gravis are well tolerated and reduce symptoms of the disease.
-
Automated Life Science A.I. Generation System Unveiled
A bioengineering lab created a system to make it easier for life scientists to use machine learning for data analysis, without writing their own algorithms.
-
Biotech Start-Up to Discover Cystic Fibrosis Therapy
A new biotechnology company is advancing research to find a comprehensive treatment for cystic fibrosis, and staked to a €2 million seed investment from its founder.
-
Synthetic Bio Company Manufactures Research Cells
A synthetic biology company says it can now produce engineered cells from stem cells for research to precise specifications, and in large quantities and consistent quality.
-
Crop Health Device Company Raises $3.5M in Early Funds
A company detecting early-stage crop diseases with handheld devices and artificial intelligence is raising $3.5 million in its seed venture round.
-
Neuro Biomarkers, Home EEG Assessed in Upcoming Trial
A digital biomarkers company and developer of neuroscience analytics are collaborating on a study of EEG measurements and algorithms with a wearable device at home.
-
Companies Partner on A.I., Fusion Energy for Space Flight
A developer of fusion energy for space travel and software company for space flight systems are writing machine learning algorithms to design a hyper-fast rocket engine.
-
Targeted Genetic Nanoparticle Company Gains $25M in Seed Funds
A developer of nanoscale lipid particles for delivering genomic therapies to specific cells and tissue, spun-off from academic labs, is raising $25 million in seed funds.
-
Vaccine Patch Shown Safe, Induces Immune Response
Initial results from a clinical trial show a patch device delivering a Covid-19 vaccine is well tolerated by recipients and triggers a measurable immune response.